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ABSTRACT 
 
Tuberculosis is a uniquely tough disease to diagnose and treat, mainly due to its unique cell 
membrane, the environment, and other socio-cultural factors. As HIV and TB rates rise in endemic 
countries, more and more people are becoming susceptible to an incurable TB infection, and more 
are being missed in the diagnostic process. Now, the need for a more sensitive diagnostic test that 
can be easily used in resource-poor settings is more necessary than ever. In this essay, a review of 
current TB diagnostic techniques used in resource-poor settings is discussed, as well as their 
drawbacks for detecting TB in the various forms of TB disease. To illustrate this point, one TB 
diagnostic clinic located in South India, is used as an example of how current techniques are used 
in resource-poor settings. Finally, the gold standard of TB diagnostics is compared to an already 
existing method adapted with the cheap and easy-to-use TB Beads. If TB Beads are in fact able to 
detect mycobacterium better, faster, and cheaper than other methods available, its importance in 
global public health and the control of TB disease is beyond measurable. 
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1.0  INTRODUCTION 
1.1 GLOBAL HISTORY OF THE TUBERCULOSIS EPIDEMIC 
Mycobacterium tuberculosis is by no means a new public health threat; it has remained silently 
endemic in our world since the existence of mankind. The genius Mycobacterium is hypothesized 
to have originated more than 150 million year ago during the Jurassic Period; and an early 
progenitor of Mycobacterium tuberculosis infected hominids in East Africa as early as 3 million 
years ago[1, 2]. However, it wasn’t until the Renaissance that mankind developed written 
documentation of TB diagnosis. René Théophile Hyacinthe Laennec, inventor of the stethoscope, 
first described the pathology of tuberculosis as well as the symptomology associated with 
pulmonary TB in terms that are still used in diagnosis today[3]. Presently, there were an estimated 
8.6 million new cases of TB worldwide in 2012 alone (Figure 1), and 1.3 million deaths due to the 
disease. And TB disease is the second leading cause of death by infectious disease, after HIV[4]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Estimated new cases of TB per 100,000 population in 2012 (WHO) 
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The driving forces behind resurgence of TB epidemics and the reasons why many countries 
hold TB endemic within their population are due to the lack of rapid point-of-care diagnostics. 
Less than 30% of the estimated number of people with TB were actually diagnosed in 2012 with 
a proven efficient diagnostic method. This is due to the fact that early TB diagnosis is dependent 
on test accuracy, accessibility, cost, and complexity, but also depends on the political will and 
funder investment. We now understand all too well that immediate and accurate diagnosis of TB 
is crucial in interrupting the transmission of Mycobacterium tuberculosis (Mtb)[4, 5].  
As TB infections have waxed and waned throughout the centuries humankind is constantly 
struggling to stay one step ahead of the disease. Now, confounding factors like HIV, over-
population, and multi-drug resistance (MDR) continue to threaten control of the disease[6]. The 
emergence of TB-HIV co-infections are quickly growing out of control; nearly one quarter of TB 
deaths in 2012 occurred in people co-infected with HIV[4]. The rapid increase in co-infection rates 
is partially due to the presenting atypical clinical symptoms, compared to those HIV-negative 
patients, causing TB detection rate to drop, and Mtb to therefore continuously spread throughout 
the community. Figure 2 illustrates that in TB- and HIV-endemic countries, less than 40% of TB 
cases were detected in 2010, emphasizing that optimal detection of Mtb infection in HIV-infected 
individuals remains a major challenge in resource-poor settings[5].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Estimated global TB case detection rates, 2010 (WHO) 
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In the 1990s new strains of Mtb have emerged that are much more expensive, time-
consuming, and toxic to treat[7]. Multidrug-resistant tuberculosis (MDR-TB) is resistant to at least 
isoniazid and rifampicin, two first-line drugs for TB treatment[8]. The WHO estimated that there 
were approximately 450,000 new cases of MDR-TB worldwide in 2012, encompassing 3.6% of 
new TB cases and 20.2% of previously treated cases. Most of the highest rates of MDR-TB are 
located in central Asia, where MDR-TB accounts for more than 20% of new infections and more 
than 50% of previously treated cases[4]. Furthermore, only 7% of the estimated 500,000 new 
MDR-TB patients are detected each year, resulting not only in inappropriate treatment and 
continual transmission of MDR-TB, but also facilitates amplification of drug susceptibility and 
resistance[5]. 
1.2 TUBERCULOSIS IN INDIA 
Over half of the estimated number of TB cases in 2012 occurred in South East Asia and Western 
Pacific, and India is one of 22 countries that accounts for approximately 80% of incident cases for 
these diseases. In 2012, India had the world’s largest number of incident cases, totaling 
approximately 2.0 to 2.4 million people. Compared with China, which had the second highest 
number of global incident infections that year, 0.9 to 1.1 million people became infected with TB. 
Figure 3 shows the enormity of the situation, where India’s TB incidence vastly outnumbers the 
other nine high burden countries. India alone accounted for 26% of the total global cases in 
2012[4].  
In 2012, the WHO designated India as a high TB, HIV, and MDR-TB burden country. TB-
HIV co-infections is a fast growing concern for the population of India. Only 56% of TB patients 
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in India knew their HIV status in 2012, 5% of which were HIV positive. TB has become a huge 
barrier to economic and social development. Every year in India, an estimated 100 million 
workdays are lost, and every three minutes two Indians will die from TB. Unfortunately, TB 
support has recently decreased in the past year and the economic burden weighs heavily on the 
population. In 2012, TB incurred nearly $3 billion in indirect costs due in part to loss of job 
productivity and financial burden left on family members[4, 9].  
 
 
 
 
 
 
 
Figure 3. Estimated TB incidence (absolute numbers): top-ten countries, 2012 (WHO) 
 
The Revised National Tuberculosis Control Program (RNTCP) is a government-run program 
created for the control of TB in India. The RNTCP provides completely free TB diagnosis and 
treatment for government and privately-run health clinics throughout the country, as well as 
incorporates principles of DOTS (Directly Observed Treatment/Therapy, Shortcourse), and the 
Stop TB Partnership developed by the WHO for comprehensive TB control[9]. Patients are able 
to access this free treatment at Designated Microscopy Centers (DMCs) located throughout the 
country. The DOTS strategy is currently used in 182 countries, and has been used in India since 
early 1993. Nine years after the program’s national launch in 1997 the RNTCP declared the entire 
population of India covered by DOTS. The program has five core components which ensure 
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quality management of TB throughout the country: 1) political and administrative commitment; 2) 
good quality diagnosis; 3) an uninterrupted supply of good quality anti-TB drugs; 4) supervised 
treatment (DOTS); and 5) systematic monitoring and accountability. 
The RNTCP estimates that more than 15,000 TB suspects are screened for TB daily in 
India, 3,500 of which are started on treatment. Diagnosis and follow-up with at least six months 
of treatment is established with over 50,000 sputum smears and laboratory specimens. Since the 
RNTCP first started, they have trained more than 600,000 health care workers and lab technicians 
in 11,500 DMCs. The RNTCP contributes their higher sputum-positive confirmed diagnosis, and 
their tripling of the treatment success rate to 86% (compared to the previous program NTP), as a 
result of their rapid expansion of DMCs and trained professionals[9]. 
However, Table 1 displays the shockingly low number of laboratories available for sputum 
smear, culture, and drug susceptibility testing for the continuously growing population of India. 
With culturing being the WHO recommended gold standard for TB diagnosis, there is less than 
one laboratory that is able to perform this technique per 15 million people. Compare these numbers 
to China and South Africa, with 11.1 and 4.2 labs available to do culturing per 15 million people, 
and we begin to understand where the mismanagement of TB diagnostics has gone so wrong in 
India. There are even fewer drug susceptibility clinics in India, with one clinic available for MDR-
TB screening per 25 million population. Regardless of this, in 2012 India had the highest number 
of laboratory-confirmed cases infected with MDR-TB, totaling 16,588, 14,143 of which were 
actually started on treatment (Table 1)[4].  
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Table 1. Number of laboratories that perform smear, culture, and drug susceptibility testing in India, 2012 (WHO) 
 
Laboratories 2012 
Smear (per 100,000 population) 1.1 
Culture (per 5 million population) 0.3 
Drug susceptibility testing (per 5 million population) 0.2 
Is second-line drug susceptibility testing available? Yes, in country 
 
1.2.1 LEPRA India and UMEED DMC, Hyderabad India 
Hyderabad is the state capital of Andhra Pradesh, located along the southeastern coast of India. As 
the fourth most populous city in India, Hyderabad is a bustling metropolis where the vibrant 
cultures of India mix with internationally rated schools, tech corporations, and a rich history. 
According to recent 2014 estimates, the city of Hyderabad has a population of approximately 8.7 
million, which has increased 28% since the last official census in 2011. 1.7 million people are 
estimated to live in 1,476 slums located across Hyderabad. Additionally, 24% of the city’s 
population are considered migrants. Due to Hyderabad’s large migrant community, overpopulated 
slums, and inadequate access to cutting-edge medical technology, Hyderabad represents an ideal 
city for evaluating the natural course of TB among its population in South India[10]. 
LEPRA India is a non-governmental organization that provides community-based services 
for TB, HIVAIDS, leprosy, malaria, lymphatic filiriasis, and basic eye care. UMEED designated 
microscopy center (DMC) is a collaborative health clinic shared between the Indian government 
and LEPRA India; one of the clinics run collaboratively by LEPRA and RNTCP, is located in the 
neighborhood of Gaddiannaram. The DMC serves a population of approximately 94,000 within 
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an area of 5km, including 20 slums with a population of 22,000. UMEED employs 34 DOTS 
providers who work at the dispensary, and 30 private medical practitioners who work at the 
adjacent 17-ward hospital. Most residents of Gaddiannaram neighborhood live within the 
catchment area of UMEED, meaning that they have legitimate and free access to the health clinic. 
UMEED is also well-known and respected in the community for its approach to the TB-HIV co-
infection epidemic, allowing co-infected patients who live outside the catchment area to access the 
clinic for treatment, education, and support.  
UMEED DMC recorded statistics of their diagnostic record ranging from 2006-2012. Over 
that timespan they tested 3,519 TB suspects, of which they found 457 to be positive for TB. During 
the same time they tested 1,823 of their follow-up patients at their two month treatment mark, 77 
of which tested positive for TB (Figure 4). No data was found regarding prevalence of MDR-TB 
concerning the 77 patients who were positive after two months of treatment, however this does not 
necessarily mean that there was no follow-up conducted. 
 
 
 
 
 
 
 
 
Figure 4. TB suspect and follow-up patients determined positive for TB by SSM, represented as percent of total 
slides examined for TB suspects and follow-ups individually, UMEED DMC, 2013 (McGuirk). 
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The Blue Peter Public Health & Research Center (BPHRC) is a clinical research facility 
funded by LEPRA India, as well as other NGO and the Indian government. The labs are divided 
into three divisions: clinical and epidemiological, immunology, and, microbiology and molecular 
biology. Their main research interests are leprosy, TB, malaria, HIV/AIDS, lymphatic filiriasis, 
and basic eye care.  
1.3 CLINICAL MANIFESTATIONS OF TUBERCULOSIS 
The type of diagnostic algorithms used for TB detection is directly related to the type of TB disease 
the patient presents with. Therefore, this section will elaborate on the different types of TB disease 
and the pathophysiology of the hosts’ immune response attributed to Mtb infection. The risk factors 
for susceptibility towards Mtb infection may be different from the risk factors involved in 
progression to active TB disease[11]. Much of what happens after Mtb infection is determined by 
geographical location, strain type, host genetic background, and immunosuppression; however, a 
lot is still unknown[5].  
1.3.1 Active TB 
Active TB infection causes a variety of symptoms, due to individual hosts’ immune response to 
various triggers[11]. As opposed to latent TB, active TB disease can take many forms, which are 
typically diagnosed by their symptomology and tests detecting the presence of Mtb. The most 
common form of active TB is pulmonary TB. Pulmonary TB is classified as an active state of TB 
disease, and is often characterized by a cough lasting two to three weeks, becoming more 
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productive throughout the course of infection as more tissue is destroyed. Other symptoms may 
include, but are not limited to: unexplained weight loss, loss of appetite, night sweats, fever, 
fatigue, chills, coughing up blood, and chest pain[12]. Although these symptoms are the most 
obvious ways to tell someone is suffering from TB disease, unfortunately only a small percentage 
of people with active TB will develop these symptoms, making cough and fever insensitive 
predictors for TB disease[13]. Pulmonary TB can be confirmed by the detection of Mtb in the 
sputum, using sputum smear microscopy as the diagnostic tool.  
1.3.2 Latent TB 
Often dubbed “the hidden epidemic”, it is estimated that one third of the world is latently infected 
with Mtb[14]. Latent TB infection is defined as a homeostasis, creating an equilibrium between 
host resistance and bacterial persistence[15]. Granulomas, a characteristic of latent TB, are a 
complex and organized collection of host inflammatory cells which have surrounded the Mtb 
infection, limiting the bacilli’s’ multiplication and dissemination throughout the body[16]. Due to 
granuloma formation, latent TB is not a form of active TB disease, therefore there are no clinical 
symptoms, nor is the patient infectious[17]. However, disruption of the granuloma structure, is 
likely to lead to reactivation of latent Mtb, and active TB disease. Factors leading to granuloma 
disruption include: chronic diseases, HIV, malnutrition, tobacco smoke, indoor air pollution, 
alcoholism, silicosis, insulin-dependent diabetes, renal failure, malignancy, and immune 
suppressive treatment, [5, 15, 16]. Approximately 10% of latently infected people will develop 
active tuberculosis in their lifetime[14]. However, it has been shown that Mtb can persist within a 
human host for decades[18]. 
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1.3.3 Extra-pulmonary TB 
Extra-pulmonary TB is a type of active TB disease in which Mtb can be found in a multitude of 
tissues and organs within the host. This state of TB disease is especially common in the 
immunocompromised host, and is often present in HIV positive individuals[19]. In addition, 
symptoms of extra-pulmonary TB are often confused with other diseases, making extra-pulmonary 
TB difficult to diagnose and treat[20]. The WHO estimated there were 0.8 million incident cases 
of extra-pulmonary TB reported in 2013. However, the global presence of extra-pulmonary TB is 
difficult to assess because the disease is not yet considered a credible threat to public health by 
those who are still struggling to control the more evident pulmonary TB. Extra-pulmonary TB may 
also not be considered the culprit as often as pulmonary TB due to that fact that it is extremely 
difficult to diagnose, especially in resource-poor settings[4].  
In the early 1980’s before the HIV epidemic, approximately 85% of reported TB cases 
were pulmonary, with the remaining 15% classified as either extra-pulmonary or a mixture of the 
two. A recent retrospective study of people co-infected with TB-HIV reported that 38% had 
pulmonary TB, 30% had extra-pulmonary TB, and 32% had both pulmonary and extra-pulmonary 
disease, detailing a significant increase in the number of extra-pulmonary TB cases[21]. Sputum 
smear-negative and extra-pulmonary TB now account for as much as 60% of all TB reports, 
especially in high HIV prevalence areas[22]. Because extra-pulmonary TB occurs at sites that are 
not readily available or dangerous for most diagnostic clinics to access, the patient will need to be 
transferred to a hospital, incurring a much higher expense or increasing the risk of patient-loss. In 
addition, because of the nature of the sites involved, fewer bacilli are necessary for a pronounced 
infection. This combined with poor accessibility to proper healthcare make bacteriologic diagnosis 
difficult in resource-poor areas[21]. 
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1.3.4  TB-HIV co-infection 
In 2012, 1.1 million people worldwide who became infected with Mtb were HIV positive; TB is 
the most common cause of mortality in HIV infected adults living in resource-poor countries [4]. 
The risk of an HIV positive person developing TB disease is between 20 to 37 times greater as 
compared to those who are HIV negative[23]. The emergence of the HIV epidemic has drastically 
changed the detection, epidemiology, and treatment outcomes for TB[24]. It is well-known that 
HIV destroys CD4 T cells, which is theorized to contribute to the susceptibility of HIV positive 
persons to Mtb infection. HIV also affects macrophages, and has influence on cytokine production, 
which may prevent the host from progressing to latent TB and contain the Mtb infection in a 
granuloma[15]. HIV infection has been shown to increase the risk of reactivating latent TB, as 
well as rapidly progressing the disease, as compared to those not infected with HIV[22]. Several 
studies in TB-HIV endemic areas have shown that HIV leads to an increased risk of developing 
TB shortly after HIV infection. For example, HIV positive South African miners were two to three 
times more likely to develop TB than their HIV negative counterparts within two years of HIV 
infection[25].  
1.4 STATISTICAL CALCULATIONS FOR DIAGNOSTIC TESTS 
The sensitivity of a diagnostic test is the probability that the test in question is positive given that 
the patient has the disease. The specificity of a diagnostic test is the probability that the test in 
question is negative given that the patient does not have the disease. For a diagnostic test to be 
effective in predicting disease, it is important that both the sensitivity and specificity be high[26]. 
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Table 2 has more detail in calculating sensitivity and specificity for a new diagnostic test when 
compared a gold standard. The positive predictive value (PPV) of a diagnostic test is the 
probability that the patient has the disease given that the test in question is positive. The negative 
predictive value (NPV) of a diagnostic test is the probability that the patient does not have the 
disease given that the test in question is negative[26]. See Table 2 for an example of calculating 
PPV and NPV. A false positive, also known as type I error, is defined as a positive test result when 
the disease being tested for is not actually present. A false negative, also known as type II error, is 
defined as a negative test result when the disease being tested for is actually present (Table 2)[26]. 
 
 
Table 2. Example of sensitivity, specificity, PPV, and NPV calculations for new diagnostic tests compared with the 
gold standard, 2014 (McGuirk) 
 
 
 
 Test positive Test negative  
Disease present True positive False negative  Sensitivity = 
Σ true positive / Σ disease positive 
Disease absent False positive True negative Specificity = 
Σ true negative / Σ disease negative 
 PPV = 
Σ true positive / Σ test 
outcome positive 
NPV = 
Σ true negative / Σ test 
outcome negative 
 
where Σ = the sum of all 
G
ol
d 
st
an
da
rd
 
Test outcome 
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2.0  A REVIEW OF CURRENT TB DIAGNOSTIC METHODS IN RESOURCE-POOR 
SETTINGS 
Despite the fact that more accurate methods are available for TB diagnosis, many laboratories 
around the world use the same methods today that were used nearly half a century ago. One 
possible reason for continuing use of these conventional methods is simply due to the lack of 
technical expertise and equipment[14]. When considering the dynamics of TB disease, using one 
diagnostic method alone may not be sensitive enough to accurately diagnose TB [21]. Therefore, 
the methods presented in this section are listed in order of their preference and simplicity, which 
is typically (but not exclusively) correlated with lower cost and less expertise needed. In addition, 
not all TB diagnostic methods are mentioned in this essay, only ones commonly used in resources-
poor settings. 
2.1 PASSIVE CASE-FINDINGS 
Passive case-finding is usually the first technique used to detect active TB in resource-poor 
settings. It is defined as identifying pulmonary TB among people who are actively seeking care, 
or in the context of TB-endemic areas, those who are aware they have been exposed to Mtb and/or 
know they are exhibiting the symptoms of TB and understand that they need medical care. 
Theoretically, passive case-finding would be the best scenario for pulmonary TB detection due 
wholly to the fact that it is free of cost for the patient and the healthcare provider. However, the 
majority of people who have been exposed to Mtb are either unaware that they are infected, 
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attribute their infection to another disease, are deterred by costs they might incur for visiting a 
clinic, or simply do not exhibit the typical symptoms of TB, and therefore do not seek treatment.  
Symptom screening is typically performed by a health care worker at a clinic. Their training and 
patient care history can vary from volunteer community health workers to possession of a medical 
degree. These patients are usually exhibiting the traditional symptoms of pulmonary TB, and are 
therefore known as “TB suspects” until their case can be confirmed by culture, smear, and/or other 
methods. The sensitivity of using symptom screening as a diagnostic tool is quite low, ranging 
from 35-84%, depending on the specific symptom being used[13]. In addition, with symptom 
screening the higher the PPV the more valuable the test is. Although clinicians cannot directly 
measure the PPV of symptoms, they can measure how often specific symptoms occur using 
sensitivity and specificity[26]. 
2.2 SPUTUM SMEAR MICROSCOPY 
Sputum smear microscopy (SSM) is the most common method for diagnosing TB in resource-poor 
settings, as well as one of the most unpredictable. A sample must be produced before SSM can be 
performed; the sample is usually sputum (for pulmonary TB diagnosis), but SSM can be used with 
other (extra pulmonary) samples as well. There are several crucial steps that must be understood 
and followed by both the patient and the technician when collecting and processing the samples, 
which leaves room for multiple errors. It is recommended that personnel observe the sputum 
collection to avoid accepting samples such as nasal discharge and saliva, which are not sputum 
(material brought up from the lungs after a productive cough). The RNTCP has recommended that 
two sputum specimens are to be collected over one, or two consecutive days, in order to improve 
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the chance of detecting Mtb by SSM. In addition, it is recommended that one of the samples be 
collected on the spot and the other collected in the early morning by the patient at home[21, 27]. 
However, providing two samples on two separate days is often a practical challenge for many 
patients who may travel far to reach a clinic that specializes in TB diagnosis and SSM[28]. 
The detection of acid-fast bacilli (AFB) in stained sputum smears from clinical samples is 
the easiest and quickest bacteriologic method to prove the presence of Mtb infection. It can also 
give a quantitative estimation of the number of bacilli being produced and the infectiousness of 
the patient. SSM was developed based on mycobacteria’s unique ability to retain fuchsin dye 
within its mycolic acids in the presence of a strong acid or alcohol. Ziehl–Neelsen (a type of 
carbolfuchsin staining) is the most common method used for acid–fast staining in resource-poor 
areas due to its low cost and quick methodology. However, studies have shown that there must be 
5,000 to 10,000 bacilli per milliliter of sputum sample in order to visualize the mycobacteria in the 
stained smear[29]. Unfortunately this bacterial load is not typical for many of the presentation that 
TB disease can take, therefore the sputum smear is far too insensitive for much of Mycobacterium 
detection.  
The Stop TB Partnership and DOTS recommends using oil immersion light microscopy 
and scanning the stained smear from left to right, covering approximately 100-150 microscopic 
100x fields. This should take about five minutes for a trained technician to complete. Since Mtb 
can be variable in shape and size, it is important for technicians to count even one bacilli as a 
positive result. The WHO recommends scanning up to 300 fields of view before reporting a 
negative result, which can be both time consuming (15 minutes per slide) and exhausting. Table 3 
shows the most common way laboratories record AFB quantifications during SSM in resource-
poor areas[30]. 
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Table 3. Recording results of AFB sputum smear quantification (The Stop TB Partnership) 
 
Finding Recording 
No AFB found in at least 100 fields negative 
1-9 AFB per 100 fields exact figure/100 
10-99 AFB per 100 fields + 
1-10 AFB per field (count at least 50 fields) ++ 
More than 10 AFB per field (count at least 20 fields) +++ 
 
 
Table 4 displays the sensitivity and specificity of SSM as compared to the gold standard of 
culturing. Factors influencing the sensitivity of SSM include, sample collection, disease state or 
type, technicians’ experience in staining and reading, and the prevalence of TB in the 
population[21]. If given the choice between symptom screening or SSM, it is not surprising that 
most clinicians would be able to give a more accurate diagnosis given the patients symptoms[5, 
13]. 
 
Table 4. Sensitivity and specificity of SSM as a diagnostic tool for pulmonary TB, using culture-confirmed 
pulmonary TB as the gold standard, 2013 (WHO) 
 
Diagnostic test Sensitivity % 
(95% confidence interval) 
Specificity % 
(95% confidence interval) 
Culture (gold standard) 100 100 
SSM 61 (31-89) 98 (93-100) 
 
 
Although smear-positive cases are the most infectious, approximately half of pulmonary 
TB case overall are sputum smear-negative, and are typically those who are 
immunosuppressed[17, 24]. In sputum smear-negative pulmonary TB, the Mtb bacterial load is so 
low in the specimen that it cannot be detected by sputum smear microscopy, which has a low 
sensitivity compared to other diagnostic methods. The Stop TB Partnership and DOTS has 
developed an algorithm (Figure 5) for effectively diagnosing pulmonary TB in resource-poor 
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settings. Due to the necessary time requirements and cost associated with these methods, sputum 
smear-negative patients are more likely to be admitted to a hospital, lost to follow-up, or simply 
diagnosed as TB negative[27].  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5. Diagnostic algorithm for pulmonary TB in resource-poor settings, 2009 (DOTS) 
 
With so many personnel, equipment, and technology invested in SSM over the decades, 
the WHO estimates that only 57% of the 4.6 million incident pulmonary TB patients in 2012 were 
bacteriologically confirmed [4]. Furthermore, the arrival of TB-HIV co-infection has completely 
changed everything we know about SSM. It is theorized that If SSM is used for diagnosis in HIV-
endemic areas, about one in five people co-infected with TB-HIV will have a negative result[21]. 
As many public health systems still struggle with finding, detecting, and treating typical TB 
patients, those co-infected with HIV presenting with abnormal symptoms are often overlooked. 
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2.3 CULTURING OF MYCOBACTERIA 
The WHO recommends that all clinical samples suspected of Mtb infection be inoculated onto 
culture media for four reasons: (1) culture is much more sensitive than microscopy; (2) culturing 
is necessary for precise identification of mycobacterial species; (3) culture is required for drug 
susceptibility testing; and (4) genotyping of cultured organisms may be useful to identify 
epidemiological links between patients. The specimens may be very viscous, holding suspected 
Mtb organisms within the sputum matrix of mucous. Therefore, before the gold standard of 
culturing can begin, it is necessary to clarify (liquefy) the sputum samples so decontaminating 
agents may kill contaminating bacteria and surviving Mtb may easily access nutrients of the culture 
medium[21]. Samples are typically clarified with N-acetyl-L-cysteine (NaLC--a mucolytic agent) 
and then decontaminated with a 1 to 2% sodium hydroxide (NaOH) solution to ensure that the 
fast-growing contaminating organisms are killed, allowing the Mtb to grow at their slower rate 
(henceforth referred to as “NaLC-NaOH”). The WHO recommends that sputum processing take 
place in a biosafety cabinet (BSC) and in a minimum biosafety level two (BSL2) laboratory[31]. 
Due to their unique cell membrane, Mtb is considered to be very robust organism that is 
able to survive in harsh environments. It was once thought that the chemicals used to 
decontaminate specimens do not affect Mtb nearly as much as the contaminating organisms. 
However, more studies are suggesting that the decontamination procedure may kill up to 90% of 
Mtb in the specimen [21, 32, 33]. Although culturing is a more sensitive technique compared to 
SSM, the significance of Mtb killing during clarification cannot be overlooked. With more 
immunosuppressed patients coming to DMCs for TB diagnosis, there is a great demand for more 
specific Mtb detection at all stages of disease, something that the culturing may not be able to offer 
as long as NaLC-NaOH is being used. 
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The sensitivity of culture is 80–85% with a specificity of approximately 98%. Three 
different types of traditional culture media are available: egg based (Löwenstein–Jensen), agar 
based (Middlebrook 7H10 or 7H11 medium), and liquid (Middlebrook 7H12). Mtb grow more 
rapidly on the agar medium (approximately 3-8 weeks) compared to Löwenstein–Jensen slants, 
and even faster in liquid media (1-3 weeks). A drawback to liquid media is the inability to isolate 
specific Mycobacterium species. Diagnostic labs in resource-poor areas tend to use Löwenstein–
Jensen (LJ) slants because Mtb tend to grow slightly better on it (although it takes 3-8 weeks), and 
it is also a cheaper alternative.  Löwenstein–Jensen slants are also used for detecting rare 
Mycobacterium strains that may not grow on the other media. Table 5 shows a commonly used 
scale for quantitating growth on Löwenstein–Jensen slants[21]. 
 
Table 5. Quantification scale for mycobacterial growth on Löwenstein–Jensen slants, 2000 (CDC) 
 
No. of Colonies Seen Quantity Reported 
No colonies seen Negative 
Fewer than 50 colonies Report actual number seen 
50-100 colonies 1+ 
100-200 colonies 2+ 
200-500 colonies (almost confluence) 3+ 
>500 colonies (confluence) 4+ 
 
A major improvement in Mtb diagnostics has been the development of commercial broth 
systems for mycobacterial growth detection. Automated culture systems such as BACTEC 460, 
Mycobacterial Growth Indicator Tube (MGIT) systems, Extra Sensing Power (ESP) Myco-
ESPculture System II, and BacT/ALERT MB Susceptibility Kit, use Middlebrook 7H12 media 
 20 
with added radiometric or colorimetric material for detection of Mycobacterium. These systems 
allow for rapid growth in liquid culture with drug susceptibility testing, whereas agar and egg-
based media allow detection of mixed cultures. Therefore, it is recommended that at least one 
Löwenstein–Jensen slant or agar plate should be inoculated when using the automated broth 
culture systems[21]. The automated broth systems are indeed faster and more sensitive in detecting 
Mtb; but, due to the initial cost of the machines, difficulty in working with radioactive materials, 
and the cost of necessary supplies for culturing, the materials needed for commercial culturing 
machines are currently too high for most resource-poor health systems[34]. 
Culturing is considered the gold standard of Mtb diagnostics, and despite several 
hindrances it is still the most precise and inexpensive way to determine the species and drug 
susceptibility of Mtb. Delay in TB diagnosis due to the lengthy culturing time is still a large 
problem globally, resulting in increased morbidity and prolonged transmission[34]. Unfortunately, 
it is known that by the time an active TB case is detected, they have already infected many of their 
close contacts[35]. With up to eight weeks turnover time many patients may be lost to follow-up 
by the time their results come in. In addition, significant killing of Mtb during the clarification and 
decontamination process necessary for culturing may lead to more false negatives and untreated 
patients. One of the major drawbacks to culturing is that clinicians must have access to a laboratory 
with trained professionals running at a biosafety level three (BSL3) level capacity. This is an 
incredibly huge expense to incur in many areas, developed or not. The current gold standard for 
Mtb diagnosis in resource-poor areas is beyond ideal. 
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2.4 NUCLEIC ACID AMPLIFICATION TESTS 
The relatively recent development of nucleic acid amplification tests (NAATs) has been one of the 
most important diagnostic advances for TB control in the past few decades. PCR-based methods 
can be used for quick diagnosis of TB through amplifying specific areas in the Mtb genome, 
typically with IS6110 and16S ribosomal DNA primers. In addition, the NaLC-NaOH method is 
not required Studies have found PCR to be more sensitive than smear, but less sensitive than 
culture as a diagnostic tool for TB. To improve NAAT diagnosis, real-time PCR (RT-PCR) was 
introduced to quantitate and better detect Mtb infection with a higher sensitivity compared to 
traditional PCR. One study conducted with Iranian TB patients compared conventional methods 
with RT-PCR for the detection of Mtb from clinical samples. They found that when compared to 
culturing, the sensitivity and specificity of RT-PCR were 90.2% and 97.8%, respectively. In this 
specific study RT-PCR was able to detect 1.5 x 102 to 4.3 x 103 copies of Mtb genomic DNA from 
a sample that was previously determined to be smear-negative. The sensitivity of the RT-PCR for 
culture-positive smear-positive samples was 95.4%, and its sensitivity for culture-positive smear-
negative samples was 70.8%. This is especially important when comparing this assay to culturing, 
which is incredibly time-consuming and expensive (for at least a BSL2), as well as the Xpert 
MTB/RIF (discussed later), which is a more expensive test that can basically do the same thing as 
RT-PCR[34, 36]. One drawback for RT-PCR is the machine and reagents are both more expensive 
than traditional PCR, and should not be considered unless the laboratory intends to do high-
throughput testing.  
It is worth discussing the variability of results obtained in when working with all types of 
NAATs, especially those not commercially purchased. Keeping in mind that test performance in 
routine clinical use is not expected to be as accurate as results obtained in controlled study 
 22 
conditions, a recent evaluation of six experienced Latin American diagnostic labs showed poor 
and inconsistent performance when using non-commercial PCR reagents[34]. In addition, 
regardless of how sensitive the diagnostic technique is, it is heavily reliant on the method of DNA 
extraction. Therefore, inconsistencies in NAAT diagnostic results are not only restricted by 
mistakes made during the amplification process, but also in the extraction of genomic DNA from 
the specimen. Some studies using PCR as a diagnostic test have shown different sensitivity results, 
varying from 11-81%[37]. Although this variability depends on a number of factors, studies have 
suggested that PCR results depend majorly on different DNA extraction techniques available to 
the clinical technician or researcher[38]. In addition, when considering all NAATs, the laboratory 
must have a reliable power supply connected to a back-up power source, as well as a biosafety 
cabinet for safe specimen handling. A molecular microbiology laboratory is necessary for any type 
of NAAT, where technicians need to have access to a sterilization instrument (like an autoclave or 
pressure cooker), polymerase enzyme, as well as clean, DNAse-free space for the preparation of 
PCR. 
2.5 DRUG SUSCEPTIBILITY TESTING 
Drug resistance in Mtb is mostly due to point mutations and deletions in the chromosome, and the 
variability of genes conferring drug resistance is a vast, yet slow process. Rifampicin resistance is 
due to mutations in the rpoB gene, while isoniazid resistance is due to changes in the inhA and 
katG genes. MDR-TB has been linked to treatment, clinical, and programmatic problems, where 
poor or inadequate treatment has allowed drug-resistant mutants to become the dominant 
circulating strain in some areas. It is important to note that MDR-TB is man-made, in that we 
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exposed Mtb to either wrong or mismanaged treatment methods with poor drug-adherence 
outcomes[34, 39]. 
It is recommended by the WHO that DST be performed on all clinical isolates for optimum 
treatment, although it is well-known that the majority of clinics that test for TB do not have the 
capacity to culture their samples. The WHO also recommends that DST be done for every repeat, 
failed, and/or reinfection treatment attempt in order to accurately create a personalized drug 
regimen[8]. DST should also be performed if the patient continues to produce sputum-positive 
samples after three months of treatment at their follow-up appointment[21]. Many new diagnostic 
techniques have capitalized on molecular methods that can detect mutations in these genes, 
however culturing in media with antibiotic is still the most widely accepted test today for drug 
susceptibility[34]. 
Culture-based methods of DST can be complicated by the varying levels of susceptibility 
Mtb may express, which allows the bacterium to respond to a variety of drug concentrations[40]. 
The agar or egg-based methods allow for quantifying the number of organisms that are susceptible 
to a certain drug at a known critical concentration at which wild-type strains are killed, yet mutant 
strains survive. This method, however, takes an average time of three to four months for results, 
during which the time patient is at risk for being lost to follow-up. The automated liquid and 
radiometric systems like BACTEC 460 and BacT/ALERT MB were also designed for rapid DST. 
These systems test for all primary drug susceptibility, including: isoniazid, rifampin, 
pyrazinamide, and ethambutol. However, BACTEC and some other systems can only test for 
susceptibility within one drug concentration, so in order to determine a critical concentration or if 
the strain is completely resistant to a drug, more tests will be needed. This is especially important 
for areas that have access to several treatment programs in which drug concentrations can be 
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personalized for the benefit of the patient and immediate recovery. Although the automated 
methods return results faster than agar or egg-based (several weeks), they are still slower and more 
expensive than other molecular-based DST methods available[21, 41].  
In contrast to culture-based DST, there are some NAATs that offer fast and accurate 
detection of resistance mutations. Line Probe Assay (LPA) is currently the most preferred method 
for DST[39, 40]. LPA is a basic amplification and reverse hybridization diagnostic technique for 
detecting MDR-TB. It was endorsed by the WHO in 2008 and has been commercially available 
for several years. Before LPA is started, the sputum is traditionally processed by the same 
clarification and decontamination procedure used for culturing; however studies have reported 
successful isolating of Mtb DNA for LPA directly from sputum samples[31, 41]. LPA can also be 
performed directly from an agar or liquid culture. Following clarification procedure (if necessary) 
DNA is extracted from the Mtb-suspected samples. Polymerase chain reaction (PCR) is performed 
to amplify the drug resistant gene under question using specifically labeled primers. After PCR, 
the labelled products are hybridized with specific oligonucleotide probes immobilized on a strip. 
Depending on how they are designed, the probes can adhere to specific regions of interest, like 
wild-type, or mutations. The labeled hybrids that have been captured on the strip are detected by 
colorimetric development and observed by eye. If a mutation is present in one of the probe specific 
regions, the amplified DNA will not hybridize with the relevant wild-type probe.  Mutations are 
therefore detected by lack of binding to wild-type probes, as well as by binding to specific probes 
for the most commonly occurring mutations[31].  
The GenoType MTBDRplus assay is one type of commercially available LPA that is 
designed to simultaneously detect mutations in rpoB and both inhA, and katG genes. A 2008 meta-
analysis found that the GenoType MTBDRplus assay has a sensitivity of 98% for detecting 
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rifampicin (R) resistance, and 89% for detecting isoniazid (H) resistance, and specificity of 99% 
for both R and H[41]. This assay was recently extended for the detection of XDR-TB (Genotype 
MTBDRsl)[31]. INNO-LiPA RIFTB is another LPA system which can only detection rpoB 
mutations, however it is able to detect the emergence of rifampin-resistant populations due to the 
presence of both wild-type and mutant probes[40]. 
Studies have shown that the reduction in cost of LPAs under routine diagnosis ranged from 
30 to 50% when compared to culture-based DST. However, it is cautioned that LPA should not be 
used as a replacement for culture and DST, as culture is still required in some labs for confirmation 
of smear-negative patients. Manual LPA can be used in labs processing small numbers of samples. 
Larger labs wanting to do high-throughput will require a larger initial investment, but can process 
up to 48 samples per run, with each run taking between 2 and 3.5 hours[31]. LPA systems have 
great potential for quick drug resistant detection within a variety of countries[34]. 
Xpert MTB/RIF is the first fully automated cartridge-based NAAT that enables rifampicin 
resistant detection. It was also designed for clinics with basic laboratory infrastructure and 
personnel with minimum technical skills. The assay is able to extract, concentrate, and amplify 
DNA, as well as identify targeted genes in the Mtb genome, all from unprocessed sputum samples 
in less than two hours[42]. Although Xpert MTB/RIF was originally intended for analyzing 
sputum samples, studies have shown extra-pulmonary TB samples, like biopsies, urine, pus and 
cerebrospinal fluids, have been diagnosed with rifampicin resistant Mtb using the Xpert MTB/RIF 
assay[14]. One study used culture-positive patients as a comparison and found that Xpert 
MTB/RIF had a specificity of 99.2% and a sensitivity of 90.2%. When compared with DST the 
assay correctly identified 97.6% of the samples with rifampin-resistant bacteria and 98.1% of the 
samples with rifampin-sensitive bacteria[43]. 
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Xpert MTB/RIF is a relatively low-throughput technology made for clinics which are 
geographically distant from any DST center. Therefore Xpert MTB/RIF may not be worth the 
investment of time and money for a laboratory that tests several hundred specimens a day. Studies 
have shown that the minimal training requirements needed to operate the assay and manage the 
software reporting system are often more difficult to achieve than expected. As with any NAAT 
developed for low-income settings, the error rate is expected to rise once the test is in the field due 
to a multitude of conditions, some listed previously. The results from one 11 month trial testing 
the feasibility of Xpert MTB/RIF in lower-level health care systems in India, show that after the 
“grace period” of about seven months the sub-optimal performance rate increased 
dramatically[42]. Regardless, Xpert MTB/RIF represents a huge leap in Mtb diagnosis and MDR-
TB detection. Endorsed by the WHO in 2008, Xpert MTB/RIF is the product of years of research 
and several excellent assays combined, which opened new doors for technologically advanced Mtb 
diagnosis in resource-poor settings[14]. 
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3.0  EXPERIENCE WITH CURRENT TB CLINICAL DIAGNOSTIC TECHNIQUES 
USED AT A DMC IN HYDERABAD, INDIA 
As previously discussed, the methods of data and sample collection are intrinsically important for 
the diagnostic process. Therefore, a detailed discussion about the collection and handling methods 
of data and samples at LEPRA’s UMEED designated microscopy center (DMC) is necessary to 
gain a better understanding of current diagnostic methods in South India. IRB approval for sample 
collection (discussed in Chapter 4) was met by the Blue Peter Health & Research Center’s pre-
approved study cleared by the Institutional Ethical Committee, entitled “Clinical, genetic, and 
phenotypic analysis of Mycobacterium tuberculosis strains for TB-HIV co-infected prevalent area 
in South India”. Informed consent was taken from all patients who gave samples. 
3.1 PROCESSING PATIENTS 
The typical patients who sought care at UMEED were either passive-case findings or referrals 
from another DMC; their demographics ranged from teenagers at boarding school, HIV positive 
patients, and those living in slums. The DMC typically tested new patients on Mondays, 
Wednesday, and Fridays, leaving Tuesdays and Thursday for follow-ups and re-checking of 
sputum smear slides. Upon arrival at the clinic patients were given a sheet of paper (herein called 
a patient TB card) which had their contact information, medical history, treatment information, 
and sputum smear/HIV test results. The attending doctor privately met with each patient to collect 
their symptomology, medical history, and conduct an examination. Patients were then sent to the 
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TB treatment room with their patient TB card where they continued the TB diagnostic process by 
giving a sputum sample. Figure 6 shows an example of the settings at UMEED in which patient 
TB cards are filed. The cards were organized by date of treatment started and type of TB disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. A photo of the patient TB cards and the filing system used at UMEED DMC, 2013 (McGuirk). 
3.2 COLLECTION OF SAMPLES 
The DMC began seeing patents around 9am Monday through Saturday, and the clinic 
generally stopped accepting samples around 1pm, or before lunch. Those patients who knew they 
were TB positive and/or were on DOTs used a tissue or a piece of cloth to cover their mouths upon 
entering the clinic, to prevent any further infections. Patients were instructed by the trained 
technician on the proper process for giving sputum samples in the language they were most fluent 
in. Each patient was given two sterile collection cups with screw-on lids, each with a capacity of 
about 50 mL. The technician wrote their names, TB number, and date of birth on stickers that were 
attached to each cup, as well as the letters “A” and “B” which designated the first and second 
sample given. Depending on the time of day the patient was instructed to either come back later in 
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the day or the following morning to give their second sputum sample. If the patient did not have 
trouble producing sputum they were allowed to take the second cup home to produce their second 
sample the following day when they felt prepared, and return it the same day the sample was 
produced.  Patients who were unable to produce adequate samples usually stayed on the clinics 
compound. Approximately one sample per day was unusable due to the sample consisting of spit 
or nasal discharge instead of sputum. Although this situation significantly lowers the sensitivity of 
the test, the second sample would usually consist of sputum and therefore would be the only sample 
use to test for Mtb infection. Samples were produced by patients on the DMC compound, outside, 
and a bit away from the entrance to the building, which ensured adequate ventilation and 
prevention of infecting other patients. The sputum samples were stored on an open windowsill 
leading to the lab with the caps tightly snapped/screwed on. Since the patient number would 
typically dwindle after 12 PM, SSM was performed by the technician after lunch, at approximately 
2pm. 
All patients were asked when (if at all) they had last been tested for HIV. If the patient did 
not know their HIV status they would be referred to the HIV counselor, in the same DMC building, 
for counseling and testing. Counselors gave a private session lasting about 10-15 minutes, during 
which the patient could decide if they wanted to take a voluntary HIV test; patients almost always 
decided to take the test. The patient was given a piece of paper with their TB number and a new 
HIV number with no personal identifying information like their name, date of birth, or national ID 
number. After counseling, the patient was referred to the lab where approximately 2-5 mL of blood 
was drawn by a certified technician. Blood samples labeled with identifying HIV numbers were 
left at room temperature to let the plasma separate by gravity. All blood samples collected in the 
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morning were processed around 2pm, after the patient had left. If a patient tested positive, they 
were told at their follow-up appointment along with their TB diagnosis. 
3.3 SPUTUM SMEAR MICROSCOPY 
Ziehl-Neelsen staining is recommended by The Stop TB Partnership for AFB staining and 
detection of Mtb[30]. Two microscopy slides were labeled with each patients’ four digit TB 
number as well as “A” or “B”, referring to samples one and two given by each patient. A spirit 
lamp was lit for maintaining sterility during the smear process. A small broom stick or twig was 
used to mix and select purulent or muco-purulent material from the sputum sample and transferred 
to the slide. This material from the sample was spread with the twig over an equal area to about 2-
3 cm x 1-2 cm, using circular movements without reaching the edge of the slide. Care was taken 
to make sure the smear was as even as possible and no thick mucosal portions remained. The 
smears were air-dried at room temperature for about 30 minutes; the overhead fan was often turned 
on at this point if electricity was available to speed-up the process. The specimens on the slides 
were heat fixed by slowly passing them through the spirit lamp flame three to four times. Slides 
were then placed upwards on a staining rack over the sink, making sure that they were not touching 
other slides. A new filter paper was placed in a small funnel, which was then filled with 1% carbol-
fuchsin. As the dye ran through the filter paper and funnel it completely covered the first slide 
before it was moved over the next slide, repeating the process until all the slides were covered. A 
flame was prepared by dipping cotton in surgical spirit and lighting it with a match. Forceps were 
used to move the flame under the slides allowing each slide to be heated for about 15 seconds, or 
until steam rose from the carbol-fuchsin. After 10 minutes the slides were rinsed with tap water 
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and turned to let as much liquid as possible drain off. The slides were then de-stained with 25% 
sulfuric acid, poured completely over the slides and allowing them to sit for three minutes. The 
slides were washed again with tap water, and if any pink color remained the sulfuric acid was used 
again for another 30 seconds to one minute at most. After rinsing and allowing all the remaining 
water to drain off, the slides were flooded with 0.1% methylene blue, and sat for one minute. They 
were then rinsed and tipped to allow all the excess water to drain off. The smears were left to air 
dry overnight. 
Figure 7 shows a photo of the area where sputum samples were left by patients on the 
windowsill as well as the area where SSM was performed at UMEED DMC. Note the broomstick 
used for the smear process. The slides were generally collected over a few days and examined 
twice weekly (Tuesday and Thursday) by a technician using light microscopy with oil immersion 
at 100x magnification[30]. Results were counted and recorded as recommended by the WHO and 
shown in Table 7. When a patient was determined to be TB positive they were encouraged to name 
their contacts and bring them in for testing. 
 
 
 
 
 
 
 
 
Figure 7. A photo of the area where sputum samples were left by patients and SSM was performed at UMEED 
DMC, 2013 (McGuirk). 
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3.3 PATIENTS WHO GAVE SAMPLES 
37 sputum samples were collected from patients whose sputum was tested for Mtb at the UMEED 
DMC from May 16th to July 4th 2013. Their ages ranged from 11 to 70 years with a mean age of 
30. There were 17 females and 20 males. Figure 8 and Table 6 summarizes the following patient 
disease classification, patient type, and TB/HIV test results, in terms of percent of total samples 
collected. There were three extra-pulmonary cases, two of which were in the cervical lymph nodes, 
the third being a man whose site of infection was not noted. One of the three extra-pulmonary 
cases was HIV positive. The remaining 34 patients were diagnosed with pulmonary TB. Six of the 
patients were contact cases, 10 were follow-ups, nine were new patients referred from another 
DMC, and 12 were TB suspects. Of the pulmonary TB patients, three were reinfection cases, two 
of which were co-infected with HIV. 11 of the patients were considered sputum positive, and 26 
were sputum negative based on the SSM done at the DMC. None of the contact cases were sputum 
positive, and none of the follow-ups were sputum positive, however three of them (all HIV 
positive) were referred from another DMC for their treatment and were therefore not retested. Six 
of the 12 TB suspects were sputum positive. Three patients were serologically confirmed HIV 
positive, 16 were confirmed HIV negative, and 18 had unknown HIV status when the data was 
collected. 
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Figure 8. Patient statistics summarized by: A. TB disease classification, patient type, and B. SSM and HIV test 
results, in terms of percent of total samples collected, 2013 (McGuirk).  
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Table 6. Patients summarized by disease classification, patient type, and SSM and HIV test results, 2013 
(McGuirk). 
 
Patient 
number 
Disease Classification Type of 
Patient 
DMC SSM Result HIV 
Status 
4421 Pulmonary New Referral Neg Unknown 
4422 Pulmonary New Referral 1+ (Malkapet DMC) Neg (UMEED) Neg 
4423 Pulmonary Follow-up Neg Neg 
4424 Pulmonary Follow-up Neg Neg 
4425 Pulmonary Follow-up Neg Neg 
4433 Extra pulmonary (cervical lymph nodes) Follow-up Neg Neg 
4434 Pulmonary Follow-up Neg Neg 
4435 Pulmonary TB suspect Neg Unknown 
4436 Pulmonary Follow-up Neg Neg 
4437 Pulmonary TB suspect 1+ Neg 
4438 Extra pulmonary (cervical lymph nodes) New Referral not done at UMEED Neg 
4447 Pulmonary Follow-up not done at UMEED Pos 
4448 Pulmonary TB suspect 2+ Neg 
4450 Pulmonary New referral 1+ (Malkapet DMC) not done (UMEED) Unknown 
4451 Pulmonary TB suspect 3+ Neg 
4453 Pulmonary New Referral 1+ (Malkapet DMC) Neg 
4454 Pulmonary New Referral 2+ Neg 
4466 Pulmonary Follow-up Neg Unknown 
4467 Pulmonary TB suspect Neg Unknown 
4468 Pulmonary Contact Neg Unknown 
4470 Pulmonary Contact Neg Unknown 
4471 Pulmonary Contact Neg Unknown 
4472 Pulmonary Follow-up not done at UMEED Pos 
4473 Pulmonary New referral 2+ (at DTC) Neg 
4474 Extra pulmonary Follow-up not done at UMEED Pos 
4475 Pulmonary New referral not done at UMEED Neg  
4476 Pulmonary Contact Neg Unknown 
4477 Pulmonary Contact Neg Unknown 
4478 Pulmonary Contact Neg Unknown 
4479 Pulmonary TB suspect Neg Unknown 
4480 Pulmonary TB suspect 2+ Unknown 
4502 Pulmonary TB suspect 1+ Unknown 
4503 Pulmonary TB suspect 3+ Unknown 
4504 Pulmonary TB suspect Neg Unknown 
4505 Pulmonary TB suspect Neg Unknown 
4506 Pulmonary New Referral 1+ (Malkapet DMC) Neg 
4507 Pulmonary TB suspect Neg Unknown 
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4.0  COMPARING CURRENT LABORATORY DIAGNOSTIC TECHNIQUES USED 
IN RESOURCE-POOR SETTINGS WITH NEWLY AVAILABLE DIAGNOSTIC 
METHODS 
In the process of evaluating TB diagnostic techniques used in resource-poor areas, it is important 
to assess and understand how modern clinical laboratories are using current methods and 
developing new diagnostic technology for Mtb detection. This chapter will examine the commonly 
used laboratory method of Mtb concentration from samples, by using the NaLC-NaOH method 
practiced at LEPRAs Blue Peter Public Health & Research Center (BPHRC). BPHRC has a BSL3 
which serves as a laboratory for culture-based diagnosis of TB and MDR-TB. LEPRA employs 
three technicians in the microbiology department at BPHRC to perform NaLC-NaOH clarification 
and decontamination of sputum samples, and inoculation for diagnosis by culture. However, as 
discussed previously, the NaLC-NaOH method is known to kill up to 90% of mycobacterium in 
samples[33], making culturing diagnostics not as sensitive as previously thought. Therefore, in 
addition to evaluating the use of the NaLC-NaOH method for concentration of Mtb, it will be 
compared with a new method of capturing Mtb with specialized microparticles called TB BeadsTM, 
which is a much simpler and sensitive technique for Mtb detection. The two methods will be 
compared with the samples that were previously collected and tested by SSM at UMEED DMC. 
In addition the two methods will also be compared to the gold standard of culturing.  
TB BeadsTM (Microsens Medtech Ltd., London, United Kingdom), was developed to 
provide an alternative method to capture many mycobacterial species from patient specimens, and 
concentrate the Mtb into a smaller volume size, effectively increasing the specificity for Mtb 
detection. TB-Beads are small magnetic beads coated with a polymeric ligand that binds to several 
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mycobacterium species, with minimal binding of contaminating bacteria present in the specimen. 
The ligand is made of hydrophobic chemical groups that are known to have a high affinity for 
specific materials on the mycobacterial cell surface. TB Beads are stable at room temperature and 
at high pH, which makes for an easy-to-use method for resource-poor labs to concentrate 
mycobacteria from specimens [44, 45]. In addition, the staff in the microbiology department of 
BPHRC had previously worked with TB Beads after being given a sample by the production 
company, making introduction of the technique very simple.  
4.1 NALC-NAOH METHOD 
All samples used were first tested by technicians with SSM at the UMEED DMC before they were 
transported to BPHRC. At BPHRC both sputum samples produced by the same patient (A and B) 
were mixed together and homogenized before dividing them evenly into two separate bottles in 
order to maintain even numbers of Mtb for each method of concentration. Care was used to divide 
mucosal materials evenly for even homogenization.  
This protocol was written and is currently being used by LEPRA: The following reagent 
stocks were prepared individually with distilled water and autoclaved at 121 ºC for 15 minutes: 
0.1M trisodium citrate (Na3C6H5O7), 1M sodium hydroxide (NaOH), 70 mM monopotassium 
phosphate (KH2PO4), and 65 mM disodium phosphate (Na2HPO4). Following sterilization, each 
solution was made fresh for the day. Solution 1 was made: 100 ml of 0.1M Na3C6H5O7 was mixed 
with 100 ml of 1M NaOH; as well as solution 2: 125 ml 70 mM KH2PO4 was mixed with 125 ml 
of 65 mM Na2HPO4. 0.5g of N-acetyl-L-cysteine was added to the 200 ml of solution 1 directly 
before clarification started. Twice the volume of solution 1 was added to one of each divided 
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sample in the McCartney bottle, and mixed thoroughly. This was incubated at 37 ºC for 15 minutes 
rotating. After incubation solution 2 was added up to the neck level of the bottle, which was then 
closed tightly, and mixed by inversion. The sample was then centrifuged at 3000 x g for 15 minutes 
in a sealed-bucked swing-out centrifuge. Supernatant was then poured off carefully into the discard 
container with 5% phenol. 1 ml of solution 2 was then added to the sediment and mixed well by 
pipette. The sample was split into two aliquots (0.5 ml each), one of which was stored at -20 ºC 
for back-up. 
4.2 TB BEADSTM 
The TB Beads method recommended protocol, which suggests that the specimens first be 
processed by the NaLC-NaOH method before using the beads[44], was not used. Instead, the TB 
Beads bottle was inverted several times to homogenize the solution before use. 300 µl of the beads 
was added to the second sputum aliquot and mixed by rotation at room temperature for five 
minutes. The beads were then collected on the bottom of the bottle using a magnet. The supernatant 
was removed from the top without disturbing the beads. The beads were then washed with 3 ml of 
1x phosphate buffer solution (PBS). The solution was inverted occasionally and incubated at room 
temperature for no more than three minutes. The magnet was again used to collect the bead as the 
supernatant was removed. The beads were finally resuspended in 300 µl of 1x PBS, half of which 
was stored at -20 ºC for back-up. For simplicity, Mtb was not eluted off the beads, which was also 
an adaptation from the original protocol. 
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4.3 CULTURING 
The gold standard of culturing was used to compare the Mtb detection rates among the two 
concentration methods. After concentration by the NaLC-NaOH, an inoculating loop was used to 
pick-up the freshly decontaminated and clarified sputum, which was inoculated onto two separate 
LJ slants, incubated at 37 ºC for four to six weeks. Samples from the TB Beads method could not 
be cultured because they were not decontaminated and therefore contained common flora found in 
the airways and mouths of humans, which would overgrow and interfere with the culturing of 
slow-growing Mtb. 
4.4 ZIEHL–NEELSEN AFB STAINING 
Each sample processed by both methods (NaLC-NaOH and TB Beads) was smeared onto a glass 
slide and was prepared for Ziehl–Neelsen AFB staining, the same staining method that was used 
in SSM. AFB staining was chosen because it is the fastest and most commonly used method for 
Mtb detection in clinical diagnostics. In addition, most clinics are likely to know Ziehl–Neelsen 
staining, and the method would theoretically be easier to teach and adapt to. AFB staining was 
done as described previously; 20 fields of view were examined per slide, and Mtb bacilli were 
counted and recorded. 
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4.5 RESULTS 
Figure 9 consists of microscopic images of two randomly chosen samples, both processed by 
NaLC-NaOH and TB Beads individually, and after AFB staining. Mtb bacilli are circled. The black 
areas in the TB Beads samples are aggregates of the magnetic beads. Interestingly, no bacilli were 
recorded in sample 4480 after NaLC-NaOH processing; also note the complex matrix (blue) of the 
remaining intact sputum. Table 7 summarizes the patients results from the DMC SSM, HIV status, 
and NaLC-NaOH and TB Beads concentration methods compared to the gold standard of 
culturing. 11 of the samples that were tested by SSM at the DMC were Mtb positive. Of the samples 
prepared by the NaLC-NaOH method, nine were Mtb positive, four of which were considered 
scanty (defined as an average of 0.5 bacilli per field of view). Of the samples concentrated by the 
TB Beads method, nine were Mtb positive, three of which were considered scanty. Only six of the 
samples that were concentrated with the NaLC-NaOH method and cultured were positive for Mtb. 
It is important to note that a few of the samples that were positive in both the TB Beads and the 
NaLC-NaOH method were negative in SSM and culturing. In addition, one sample that was 
positive by the TB Beads method was negative in the NaLC-NaOH method, and vice versa.  
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Figure 9. Microscopic examination of two samples treated with NaLC-NaOH and TB Beads methods after AFB 
staining, 100x magnification oil immersion, 2013 (McGuirk). 
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Table 7. Patients summarized by DMC SSM result, HIV status, and NaLC-NaOH and TB Beads concentration 
methods compared to culturing diagnostic results, 2013 (McGuirk). 
 
Patient 
number 
DMC SSM Result HIV Status NaLC-NaOH 
AFB stain result 
TB Beads AFB 
stain result 
Culture 
4421 Neg Unknown Neg Neg Neg 
4422 1+ (Malkapet DMC) Neg (UMEED) Neg Neg Neg Neg 
4423 Neg Neg Neg Neg Neg 
4424 Neg Neg Neg Neg Neg 
4425 Neg Neg Neg Neg Neg 
4433 Neg Neg Neg N/A Neg 
4434 Neg Neg Neg N/A Neg 
4435 Neg Unknown Neg N/A Neg 
4436 Neg Neg Neg N/A Neg 
4437 1+ Neg Scanty  Pos Pos 
4438 not done at UMEED Neg Neg Sample missing Neg 
4447 not done at UMEED Pos Neg Pos Neg 
4448 2+ Neg Pos Pos Pos 
4450 1+ (Malkapet DMC) not done (UMEED) Unknown Neg Neg Neg 
4451 3+ Neg Pos Pos Pos 
4453 1+ (Malkapet DMC) Neg Neg Neg Neg 
4454 2+ Neg Pos Pos Pos 
4466 Neg Unknown Neg Neg Neg 
4467 Neg Unknown Neg Neg Neg 
4468 Neg Unknown Neg Scanty Neg 
4470 Neg Unknown Neg Neg Neg 
4471 Neg Unknown Neg Neg Neg 
4472 not done at UMEED Pos Sample missing Neg Neg 
4473 2+ (at DTC) Neg Scanty  Neg Neg 
4474 not done at UMEED Pos Scanty  Neg Neg 
4475 not done at UMEED Neg  Scanty  Scanty Neg 
4476 Neg Unknown Neg Neg Neg 
4477 Neg Unknown Neg Neg Neg 
4478 Neg Unknown Neg Neg Neg 
4479 Neg Unknown Neg Neg Neg 
4480 2+ Unknown Neg Scanty Pos 
4502 1+ Unknown Pos Pos Pos 
4503 3+ Unknown Pos Neg Neg 
4504 Neg Unknown Neg Neg Neg 
4505 Neg Unknown Neg Neg Neg  
4506 1+ (Malkapet DMC) Neg Neg Neg Neg 
4507 Neg Unknown Neg Neg Neg 
 
Table 8 displays the sensitivity, specificity, PPV (positive predictive value), and NPV 
(negative predictive value), of each test comparison. Compared to the NaLC-NaOH and culturing 
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method, samples tested by SSM had a 100% sensitivity and an 84% specificity; SSM had a 54% 
PPV and a 100% NPV. Compared to the SSM method done at the DMC, samples tested by the 
NaLC-NaOH method had a 63% sensitivity and a 92% specificity; NaLC-NaOH had a 78% PPV 
and an 86% NPV. Compared to the NaLC-NaOH and culturing method, samples tested by the 
NaLC-NaOH method alone had an 83% sensitivity and an 87% specificity; NaLC-NaOH had a 
55% PPV and a 96% NPV. Compared to SSM, TB Beads samples had a 54% sensitivity and an 
88% specificity; TB beads had a 67% PPV and an 82% NPV. Compared to NaLC-NaOH method, 
samples processed with TB Beads had a 67% sensitivity and an 89% specificity; here TB Beads 
had a 67% PPV and 89% NPV. When samples that were prepared by the NaLC-NaOH method 
followed by culturing, were compared to the TB Beads concentration method, TB Beads samples 
had a 100% sensitivity and a 90% specificity; TB Beads had a 67% PPV and a 90% NPV.  
 
Table 8. Results of comparing sensitivity, specificity, PPV, and NPV among three Mtb detection methods with the 
gold standard of culturing, using a denominator of 37 total samples, 2014 (McGuirk). 
 
Diagnostic methods Preparation methods N positive* Sensitivity Specificity PPV NPV 
Culture vs. SSM NaLC-NaOH, culture vs. SSM 6 vs. 11 100% 84% 54% 100% 
SSM vs. NaLC-NaOH SSM vs. NaLC-NaOH, AFB stained 11 vs. 9 63% 92% 78% 86% 
Culture vs. NaLC-NaOH NaLC-NaOH, culture vs. NaLC-NaOH, AFB stained 6 vs. 9 83% 87% 55% 96% 
SSM vs.  
TB Beads 
SSM vs. TB Beads, AFB 
stained 11 vs. 9 54% 88% 67% 82% 
NaLC-NaOH vs. TB 
Beads 
NaLC-NaOH, AFB stained 
vs. TB Beads, AFB stained 9 vs. 9 67% 89% 67% 89% 
Culture vs. TB Beads NaLC-NaOH, culture vs. TB Beads, AFB stained 6 vs. 9 100% 90% 67% 90% 
 
 
*The number of positive results from each of the two tests compared.  
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Of the three patients that were HIV positive, none of them had their sputum tested by SSM 
during this analysis, therefore a complete comparison of the two concentration methods cannot be 
made between SSM and HIV positive patients. After NaLC-NaOH concentration, one patient was 
negative for Mtb, the second was missing, and the third was scanty for Mtb. In comparison, after 
TB Beads concentration and AFB staining of the three HIV positive patients’ samples: one sample 
was positive for Mtb with at least two bacilli per field of view, and the last two were negative for 
Mtb. Interestingly, the one that was positive was not the same sample as the positive scanty with 
the NaLC-NaOH method. All three of the samples were negative by LJ slant culture. 
It is important to note that because some TB positive patients were referred from another 
DMC, UMEED did not collect sputum to re-test them. Therefore, only two of the nine new referral 
patients were re-checked by SSM, since they were assumed to be sputum-positive. In addition, 
some of these patients had started their anti-TB therapy, which could have also altered the chances 
for Mtb detection. Most of the referred patients only gave one sputum sample (opposed to the 
WHO recommended two) due to miscommunication and incomplete direction given by technicians 
and myself; this could have also significantly reduce the detection rate of Mtb. Keeping all this in 
mind, only one of the nine samples from referral patients was culture positive. Interestingly, three 
of nine samples were positive by the NaLC-NaOH concentration method, two of which were 
considered scanty; two of eight (one sample was missing) samples were positive by the TB Beads 
method, one of which was scanty. Both of the positive samples that were not scanty from each 
concentration method were from the culture positive sample. 
One drawback to the TB Beads method is the samples are not clarified, and many of them 
remained viscous and difficult to manipulate. NaLC-NaOH clarification used to be a necessary 
component for diagnostic culturing, due to N-acetyl-L-cysteine’s mucolytic activity on the sputum 
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matrix. However, there are now commercial products available with dithiothreitol (DTT), which 
has been shown to significantly decrease the viscosity of the sputum as compared to NaLC 
methods[46]. In addition, products with DTT like Sputagest SelectavialTM, has also been found to 
yield a higher number of organisms after processing and culturing the sample as compared to 
NaLC methods[47]. If this study were to be repeated, it is hypothesized that the use of Sputagest 
with TB Beads could drastically increase the Mtb detection rate.  
In terms of processing time, TB Beads took approximately 10 minutes per sample, and is 
capable of being scaled up if necessary to anywhere from 10-20 samples per run. In comparison, 
the NaLC-NaOH method takes approximately 45 minutes per sample, accommodating about 16 
samples per run. In addition, TB Beads does not need a centrifuge for processing as compared to 
the NaLC-NaOH method. Additionally, the WHO does recommend that a BSL3 and a BSC be 
used when working with specimens to avoid possible infection. However, as discussed earlier, 
SSM (which also involves manipulation of specimens) can be done in the DMC. A BSL3 is 
definitely important for safety of the laboratory technicians in terms of infection prevention; 
however, the TB Beads method involves such little processing and no centrifugation of the sample, 
a BSC could be added to a DMC laboratory for an improved diagnostic method using TB Beads 
and SSM. This may reduce the cost of setting up a BSL3 and make a more sensitive diagnostic 
technique easily available for many resource-poor clinics globally. 
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5.0  CONCLUSION 
5.1 DISCUSSION 
In evaluating diagnostic methods for TB disease in resource-poor areas, it is important to 
understand not only the methods that are available, but also how they are used, and whether this 
affects the outcome of the tests results. Chapter two reviewed current diagnostic techniques of TB 
used in resource-poor settings. Each technique had its advantages and disadvantages, and it was 
ultimately concluded that although we are getting closer to a more sensitive method of TB 
diagnosis, there are still many barriers that need to be overcome. The issue of poor TB diagnostics 
is just the tip of the iceberg. When evaluating this public health issue it is important to understand 
the impact that unavailable resources make when comparing TB diagnosis globally in resource-
poor countries. A health network is bound to fail when the infrastructure of public health systems 
are compromised, either through lack of funding, supplies, qualified personnel, or inadequate 
government involvement. Ultimately what is needed in every community is a stable testing center 
with highly trained professionals and reliable equipment with a steady stream of supplies. Only 
when those issues are addressed can we begin to develop a more sensitive test. Many countries, 
like India, have developed strong programs (The Stop TB Partnership, for example) that offer great 
promise for the control of TB. Unfortunately, a lot of these plans do not address the social and 
cultural factors surrounding TB and TB-HIV co-infections, and therefore the execution of these 
plans are ineffective. As previously discussed, every community is different and every patient 
responds differently to their infection based on many biological, cultural, and environmental 
factors. 
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The goal of chapter three was to give an objective view of current TB diagnostics and the 
challenges encountered, and not to single-out one DMC. Additionally, how this DMC functions 
cannot be generalized throughout the world, as TB, HIV, funding, infrastructure, and social factors 
are presented differently in various locations globally. Keeping this in mind, UMEED DMC is, in 
my opinion, a shining light in the shadow of the TB epidemic. Having worked with several clinics 
in developing countries, UMEED DMC is by far the most organized and well-staffed that I have 
ever worked with. Their collaborative efforts with the government and their intelligent and highly 
driven workers gives hope that they will reach the people most in need of help. Therefore, the most 
important note I took away from my time at UMEED is that every clinic operates as an adaptation 
to best meet their patient’s needs. To an outsider it may look like UMEED had an unorganized 
process for TB diagnosis; however, they were doing what best worked for them, and nothing in 
their TB diagnostic process was glaringly wrong. In addition, UMEED was the clinic that difficult 
TB cases were sent to, especially those who were co-infected, re-infection, or re-treatment patients. 
Chapter four consisted of comparing different types of laboratory-based diagnostic 
methods that are either currently being used in resource-poor settings, or new methods that can be 
easily added to a laboratory’s protocol. The most important comparisons that can be made are 
between the three different methods of Mtb detection (SSM; NaLC-NaOH and AFB staining; TB 
Beads and AFB staining) and the gold standard of culturing. When SSM was compared to 
culturing, SSM had an expected sensitivity and specificity, with 100% and 84% respectively, 
which are acceptable numbers for Mtb diagnostics. However, when the NaLC-NaOH 
concentration method was compared to culturing, NaLC-NaOH samples had lower percentages, 
with an 83% sensitivity and an 87% specificity. The difference between SSM and NaLC-NaOH 
could be due to many environmental and processing errors. It is important to note that the gold 
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standard for Mtb diagnosis is not a perfect test. As previously discussed, culturing can only be 
done after the NaLC-NaOH method, which is now known to affect Mtb. This may be another 
explanation as to why the sensitivities and specificities varied among the tests. Regardless of these 
reasons, when the TB Beads concentration method wass compared to the gold standard of 
culturing, TB Beads had a 100% sensitivity and a 90% specificity, both as high as or higher than 
any other test used.  
The number of bacilli per field of view varied depending on the mucosal consistency, time 
of day the sample was produced, how many samples given by the patient, if the patient had started 
treatment, and if the samples were produce properly by the patient. Obviously a lot of these 
variables are intrinsically linked with patient presentation of their individual TB disease, and 
therefore un-controllable. The sample size was also too small to make any significant conclusion 
about the sensitivity of TB Beads in comparison to the NaLC-NaOH concentration method and 
culturing. However, this was the first noted occurrence of TB Beads being used to concentrate Mtb 
from a whole, un-processed sputum sample, which shows promise for more trials. 
Although TB Beads have great promise for a more sensitive detection of Mtb infection, the 
idea was not met with great enthusiasm at BPHRC. Despite recent evidence, the NaLC-NaOH 
clarification and decontamination procedure followed by culturing is still considered by some to 
be a flawless and ultimate test for Mtb detection. However, the fact remains that several samples 
processed by both the NaLC-NaOH method and TB Beads were positive after AFB staining that 
were later declared negative by culture. Based on all the presented information, a concentration 
method that involves TB Beads and whole sputum samples while circumventing the NaLC-NaOH 
process has the potential to be much faster, cheaper, easier, and more sensitive/specific as 
compared to culturing. 
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The TB Beads concentration method clearly has great potential for increasing Mtb 
detection in DMCs globally; however, it is still unknown if TB Beads are sensitive-enough for 
SSM detection of low-load Mtb cases, commonly seen in the immunocompromised, children, the 
elderly, and newly infected cases. One of the major difficulties encountered when working with 
mycobacterium is lysing the cell. As discussed previously, some of the most accurate diagnostic 
tests amplify Mtb genomic DNA extracted from the specimen. A few enzymes are currently being 
studied at the University of Pittsburgh, in Pittsburgh Pennsylvania. TDMH (Trehalose 6,6’-
dimycolate hydrolase) and mycobacteriophage lysins both target different parts of the 
mycobacterial cell wall and ultimately lyse the cell[48, 49]. They are hypothesized to help the 
release of genomic DNA during the lytic process, and are therefore candidates to be part of the 
future of Mtb diagnostics. 
5.2 PUBLIC HEALTH SIGNIFICANCE 
There are public health systems currently in India that have a strong promise for the control of TB. 
If given the correct tools, like a more sensitive test for Mtb infection that is easy to use and store, 
they have the potential to help relieve the burden of TB in a population, allowing the community 
to gain control of the disease and manage it in an organized fashion. More investigations will be 
needed before TB Beads can be used routinely in clinics globally. However, there is great promise 
that TB Beads can be used in whole, unprocessed sputum samples for the quick and cheap 
concentration and detection of Mtb, as compared to the NaLC-NaOH method and culturing. In 
addition, because the materials needed for TB Beads are commonly available in most clinics even 
in resource-poor areas, few adaptations will be needed to prepare for this new method. As of now 
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TB beads are not endorsed by the WHO to be used as a diagnostic tool in clinics, and it may take 
years for this to take place, if ever. In conclusion, if the world’s burden of TB diagnosis is to be 
overcome, the public health infrastructure will need to adapt for better diagnosis of TB disease. 
Only when we recognize and fix the incomplete state of TB response will we be able to address 
the diagnostic issues surrounding the disease. 
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APPENDIX A: GLOSSARY OF TERMS 
BSL-3 Laboratory: This level is applicable to clinical, diagnostic, teaching, research, or 
production facilities in which work is done with indigenous or exotic agents which may cause 
serious or potentially lethal disease after inhalation. It includes various bacteria, parasites, and 
viruses that can cause severe to fatal disease in humans, but for which treatments exist.  All 
procedures involving the manipulation of infectious materials are conducted within biological 
safety cabinets, specially designed hoods, or other physical containment devices, or by personnel 
wearing appropriate personal protective clothing and equipment. 
Clarification: The process by which the sputum matrix is broken down to allow access to Mtb for 
diagnostic detection.   
DST: The testing of a strain of Mtb for its susceptibility or resistance to one or more anti-TB drugs. 
Follow-up: The term for testing a TB patient for MDR-TB with SSM who has been on anti-
tubercular drugs for two months. 
Gold standard: Any standardized clinical assessment, method, procedure, or measurement of 
known validity and reliability which is generally taken to be the best available, with which new 
tests are compared with. 
Lysis: The disintegration of a cell by rupture of the cell wall or membrane. 
Referral case: A type of TB patient who is sent to another DMC, most-likely due to the specialties 
of that DMC or location in association with the patients’ home. 
Re-infection case: A patient who was previously declared cured or treatment completed and is 
diagnosed with bacteriologically TB; also known as “relapse”. A type of retreatment patient. 
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RT- PCR: A laboratory technique based on PCR, which is used to simultaneously amplify and 
quantify a targeted DNA molecule. For one or more specific sequences in a DNA sample, Real 
Time-PCR enables both detection and quantification.  
Sputagest SelectavialTM: A reagent for clarifying sputum that contains DTT, an alternative to 
NaLC used in the NaLC-NaOH decontamination and clarification method of concentration Mtb 
from specimens. 
TB BeadsTM: (Microsens Medtech Ltd., London, United Kingdom) Small magnetic beads coated 
with a polymeric ligand that binds to several mycobacterium species. Commercially used as a 
concentration method for Mtb detection and diagnosis. 
TB suspect: An individual with any symptom of TB infection or who tested positive on sputum 
culture during screening. 
Treatment failure: A patient who was initially smear-positive and who remained smear-positive 
at month five or later during treatment. A type of retreatment patient. 
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APPENDIX B: ACRONYMS 
AFB:  Acid fast bacilli 
BSC: Biosafety cabinet 
BSL3: Biosafety level three laboratory 
DMC: Designated microscopy center 
DOTS: Directly Observed Treatment, Short-course 
DST: Drug susceptibility test 
DTT: Dithiothreitol 
LJ: Löwenstein–Jensen 
MDR-TB: Multiple drug resistant tuberculosis  
Mtb: Mycobacterium tuberculosis 
NAAT: Nucleic acid amplification test 
NaLC: N-acetyl-L-cysteine 
NPV: Negative predictive value 
PBS: Phosphate buffer solution 
PCR: Polymerase chain reaction 
PPV: Positive predictive value 
RNTCP: Revised National Tuberculosis Control Program 
RT-PCR: Real-time polymerase chain reaction  
SSM: Sputum smear microscopy 
TDMH: Trehalose 6,6’-dimycolate hydrolase 
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